Biocompatible strain sensors for continuous monitoring of tumor progression during immunotherapy treatments

生物相容性应变传感器，用于在免疫治疗过程中持续监测肿瘤进展

• 批准号: 10163050
• 负责人: Alex Abramson
• 金额: $ 6.6万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-08 至 2022-05-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163050
• 关键词: Aftercare; Animals; Area; Back; Biosensor; Body Temperature; Breast Cancer Model; Cell Death; Cells; Clinical; Combination immunotherapy; Communication; Data; Development; Devices; Disease; Drug Combinations; Drug Prescriptions; Electric Conductivity; Ensure; Exhibits; Fatty acid glycerol esters; Goals; Growth; Health Professional; Hour; Image; Imaging Techniques; Immune; Immune checkpoint inhibitor; Immunotherapy; Implant; Individual; Kinetics; Location; Malignant Neoplasms; Mammary Neoplasms; Measurement; Measures; Mechanics; Methods; Modeling; Molecular; Monitor; Mouse Mammary Tumor Virus; National Institute of Biomedical Imaging and Bioengineering; Outcome; Output; PET/CT scan; Patients; Pattern; Peripheral; Pharmaceutical Preparations; Physiologic pulse; Polymers; Power Sources; Process; Reading; Research; Research Personnel; Resistance; Scanning; Series; Signal Transduction; Stress; Stretching; Subcutaneous Tissue; System; Techniques; Technology; Technology Transfer; Telemetry; Temperature; Tendon structure; Testing; Therapeutic; Time; Tissues; Treatment Efficacy; Treatment Protocols; Tumor Burden; Wireless Technology; X-Ray Computed Tomography; biomaterial compatibility; cancer therapy; checkpoint therapy; clinically relevant; cost; data exchange; design; electric impedance; experience; experimental study; flexibility; follow-up; implantation; implanted sensor; mammary; microCT; minimally invasive; mouse model; new technology; prevent; programmed cell death protein 1; response; sensor; standard of care; subcutaneous; success; treatment effect; treatment strategy; trend; tumor; tumor growth; tumor progression; wireless communication

Project Summary/Abstract: Checkpoint inhibitor therapies provide the ability to treat several previously intractable tumor types; however, only a fraction of patients eligible for the medications respond favorably. Currently patients receiving these treatments must undergo a series of costly imaging sessions to determine their tumor’s response to the medication, yet imaging only provides a static picture of the disease. Health care professionals often wait months before ordering imaging sessions in order to ensure that meaningful tumor growth or recession has occurred according to the iRECIST criteria. The goal of this proposed research is to develop an implantable strain sensor to continuously monitor tumor size throughout the treatment and provide clinicians and cancer researchers with the ability to monitor tumor kinetics. We plan to treat a mouse model for mammary cancer with a combination immunotherapy treatment and use our sensor to continuously detect minute changes in tumor size. We will then look for trends in the data that may provide clues of a positive response, especially within the first 48 hours after treatment when immune cells are known to infiltrate the tumor and cause it to temporarily expand. We hope that this new technology will be used as a method for clinicians to more accurately determine the best time to take a follow up CT scan, and we also believe that this technology could be used to study the relationship between molecular signals and tumor progression. However, in order to develop this type of sensor, we must overcome two fundamental design constraints: the large size associated with power storage and wireless data transfer; and the ability for a sensor to grow and conform to rapidly expanding tissue. Part of the proposed research is to develop a platform technology for transferring power and sensor readings conductively through the body, thereby eliminating the need for a battery and telemetry system and shrinking the device size significantly. We also plan to utilize flexible and stretchable electronic materials developed in our lab to design a device which can expand alongside tissue without exerting any force that could damage the surrounding tissue. We believe that these technologies could be used for a variety of purposes in addition to measuring tumor size and could enable to widespread routine clinical use of implantable biomedical sensors.

项目概要/摘要： 检查点抑制剂疗法提供了治疗几种先前难治性肿瘤类型的能力;然而， 只有一小部分符合药物治疗条件的患者反应良好。目前，接受这些治疗的患者 治疗必须经历一系列昂贵的成像过程，以确定他们的肿瘤对化疗的反应。 药物治疗，但成像只能提供疾病的静态图像。医疗保健专业人员通常要等上几个月 在订购成像会话之前，以确保发生有意义的肿瘤生长或衰退 根据iRECIST标准。本研究的目的是开发一种可植入的应变传感器 在整个治疗过程中持续监测肿瘤大小，并为临床医生和癌症研究人员提供 监测肿瘤动力学的能力。我们计划用一个乳腺癌的小鼠模型， 免疫治疗和使用我们的传感器连续检测肿瘤大小的微小变化。然后我们将 在数据中寻找可能提供积极响应线索的趋势，特别是在事件发生后的前48小时内。 当已知免疫细胞浸润肿瘤并导致其暂时扩大时进行治疗。我们希望 这项新技术将被用作临床医生更准确地确定最佳服用时间的方法。 随访CT扫描，我们也相信这项技术可以用来研究 分子信号和肿瘤进展。然而，为了开发这种类型的传感器，我们必须克服 两个基本的设计限制：与电力存储和无线数据传输相关的大尺寸; 以及传感器生长并适应快速扩张的组织的能力。拟议研究的一部分是 开发一种平台技术，用于通过身体传导传输功率和传感器读数，从而 消除了对电池和遥测系统的需要，并且显著地缩小了设备尺寸。我们还计划 利用我们实验室开发的柔性和可拉伸的电子材料来设计一种可以扩展的设备， 而不施加任何可能损伤周围组织的力。我们相信这些 除了测量肿瘤大小之外，这些技术还可以用于各种目的， 植入式生物医学传感器的广泛常规临床使用。